|
gptkbp:instanceOf
|
gptkb:drug
small molecule
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2012
|
|
gptkbp:ATCCode
|
L01XE21
|
|
gptkbp:brand
|
gptkb:Stivarga
|
|
gptkbp:CASNumber
|
755037-03-7
|
|
gptkbp:chemicalFormula
|
C19H15ClF4N4O3
|
|
gptkbp:developedBy
|
gptkb:Bayer
|
|
gptkbp:eliminationHalfLife
|
20-30 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
regorafenib
|
|
gptkbp:KEGGID
|
D09913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
multi-kinase inhibitor
|
|
gptkbp:metabolism
|
gptkb:UGT1A9
gptkb:CYP3A4
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
99%
|
|
gptkbp:PubChem_CID
|
11167602
DB08896
CHEMBL1945277
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
anorexia
fatigue
hypertension
weight loss
hand-foot skin reaction
|
|
gptkbp:synonym
|
gptkb:BAY_73-4506
|
|
gptkbp:target
|
gptkb:FGFR
gptkb:PDGFR
gptkb:VEGFR
RAF kinases
|
|
gptkbp:UNII
|
4ICL5A1V41
|
|
gptkbp:usedFor
|
gptkb:gastrointestinal_stromal_tumor
colorectal cancer
hepatocellular carcinoma
|
|
gptkbp:bfsParent
|
gptkb:PDGFRB
gptkb:VEGFR2
gptkb:CYP3A4_gene
gptkb:KDR
|
|
gptkbp:bfsLayer
|
6
|